The litigation targets the period between August 8, 2024, and May 13, 2026, a timeframe marked by a dramatic shift in how analysts viewed the digital health platform. While Doximity management previously touted record engagement metrics, the lawsuit asserts that these figures masked a reality where the company was losing market share to newer programmatic and social advertising formats. This discrepancy allegedly kept stock prices artificially high before the market corrected following revised guidance.

Investors witnessed significant volatility as the company’s financial narrative unraveled. Shares dropped 13% on November 7, 2025, followed by a 17% decline on February 6, 2026, after the firm lowered its fiscal revenue projections. The situation culminated on May 14, 2026, when the stock fell an additional 23% to $18.01. Analysts from firms including Jefferies and Leerink Partners subsequently downgraded the stock, with some moving the company into what they described as a "penalty box" due to the shock of the guidance reduction. The deadline for shareholders to petition as lead plaintiff in the case is November 16, 2026.